David Cameron, a paid adviser for US biotech gene-sequencing company Illumina, told Matt Hancock he strongly endorsed the firm s invitation to the then-Health Secretary in April 2019.
Zymergen Rallies 8% Pre-Market After Cathie Wood Buys 2 47 Million Shares zerohedge.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zerohedge.com Daily Mail and Mail on Sunday newspapers.
Why Zymergen s Stock Is Skyrocketing Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
By Ari Levy, CNBC •
Updated 5 hours ago
Mark Neuling | CNBC
Zymergen went public at $31 a share in April and traded as high as $48.50, valuing the company at $4.8 billion.
The stock sank to $11.07 after hours on Tuesday, leaving its market cap at just over $1 billion.
The company has yet to start generating product sales and said it now expects revenue from its products to be immaterial through 2022.
A little more than three months after pricing its IPO at the top of its expected range and soaring out of the gate, Zymergen is warning investors that revenue from its experimental products won t be coming anytime soon.
By Ari Levy, CNBC •
Updated on August 3, 2021 at 8:15 pm
Mark Neuling | CNBC
Zymergen went public at $31 a share in April and traded as high as $48.50, valuing the company at $4.8 billion.
The stock sank to $11.07 after hours on Tuesday, leaving its market cap at just over $1 billion.
The company has yet to start generating product sales and said it now expects revenue from its products to be immaterial through 2022.
A little more than three months after pricing its IPO at the top of its expected range and soaring out of the gate, Zymergen is warning investors that revenue from its experimental products won t be coming anytime soon.